aTyr Pharma Presents Preclinical Data for NRP2-Targeting Antibody ATYR2810 at the Connective Tissue Oncology Society (CTOS) 2026 Annual Meeting
Globe Newswire•19/11/2026•07:00 ET
0
Key Highlights
- ➤ATYR2810 substantially inhibited osteosarcoma tumor growth and lung metastasis in preclinical models
- ➤Anti-tumor effects persisted 20 days after ATYR2810 treatment ended, without overt toxicity
- ➤ATYR2810 reduced tumor recurrence after drug removal at day 25, with effects lasting to 45 days
- ➤NRP2 expression was identified on malignant osteosarcoma cells and macrophages
- ➤ATYR2810 completed GLP toxicology testing in non-human primates and cGMP manufacturing
Expert Statements
Sanjay S. Shukla, President and Chief Executive Officer of aTyr
“Osteosarcoma remains a significant unmet medical need with standard therapy that has not meaningfully improved survival in decades and patients facing very poor outcomes, particularly once the disease spreads to the lungs. The differentiated approach of ATYR2810 in targeting NRP2 positions it as a highly promising therapeutic candidate, as the potential to reduce metastases and sustain anti-tumor effects after treatment ends, without evidence of overt toxicity, could meaningfully improve outcomes for patients and families facing this devastating disease”
Leslie A. Nangle, Vice President, Research at aTyr
“ATYR2810 has shown anti-tumor effects in multiple preclinical models of aggressive cancers where NRP2 is implicated, and NRP2 has been shown to play a role in osteosarcoma angiogenesis and metastasis, which is in large part driven by an immunosuppressive tumor microenvironment”
Leslie A. Nangle, Vice President, Research at aTyr
“This latest research further supports that ATYR2810 can reprogram tumor-associated macrophages and that by targeting NRP2, ATYR2810 monotherapy can lead to substantial inhibition of tumor growth in osteosarcoma preclinical models, including human patient-derived orthotopic models and an aggressive syngeneic mouse model, as well as outstanding effects on tumor recurrence after removal of drug at day 25, with effects lasting out to 45 days. Furthermore, a reduction in lung metastases, a devastating complication of osteosarcoma, was also observed. We believe these findings provide a strong rationale for translating NRP2 inhibition into clinical studies”
ATYR2810 substantially inhibits tumor growth and metastasis of osteosarcoma to the lungs, the main driver of poor outcomes, in preclinical studies.
Anti-tumor benefits continued after treatment with ATYR2810 ended, without evidence of overt toxicity, supporting the potential of ATYR2810 in an aggressive cancer.
Get started
Create a free account to read the full story.
